アトピー性皮膚炎治療薬の市場規模、シェア、動向分析レポート：薬剤クラス別、投与経路別、流通チャネル別、地域別、セグメント予測、2025年～2030年

アトピー性皮膚炎治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のアトピー性皮膚炎治療薬の市場規模は2030年までに298億8,000万米ドルに達する見込みです。

2025年から2030年までのCAGRは9.02%で拡大する見込みです。アトピー性皮膚炎（AD）治療薬市場は、世界のアトピー性皮膚炎の有病率の増加、認知度の向上、治療需要の高さなどの要因により、成長機会が見込まれています。さらに、市場を獲得するための革新的な製品の継続的な発売は、市場シェアを獲得し優位性を維持するために企業が採用する主要な戦略です。

パイプラインにある有効性が高く副作用の少ない製品数の増加が、市場を牽引すると予想されます。例えば、アトピー性皮膚炎を適応症とする新薬は、2020年から2029年にかけて11品目が上市されると予測されています。これらには以下の薬剤クラス別が含まれます：ヤヌスキナーゼ（JAK）阻害剤、ホスホジエステラーゼ-4（PDE-4）、インターロイキン-4&-13（IL-4/13）などです。これらの新薬の上市は、重度および中等度のAD患者にQOLの改善と治療の選択肢の拡大をもたらすものです。

ファストトラック指定などの規制当局からの支援は、ADの研究開発を促進すると予想されます。例えば、デミラ社のレブリキズマブはファストトラック指定を受けました。さらに、2020年10月には、Forte Biosciences, Inc.の医薬品FB-401がFDAからファストトラック指定を受けました。したがって、研究開発に対する企業の関心の高まりが市場の成長を促進すると予想されます。

アトピー性皮膚炎の新規治療法の研究開発に対する資金提供の増加と政府の積極的な取り組みが、地域の成長を後押しすると思われます。公的団体と民間団体の協力により、世界中で消費者の認識が高まると予想されます。例えば、2022年6月、大塚製薬株式会社（大塚ホールディングス）は、AD治療薬モイゼルト軟膏（一般名：ジファミラスト）の日本での発売を発表しました。本剤は、非ステロイド系の外用ホスホジエステラーゼ4型阻害剤です。

日本では日本皮膚科学会（JDA）がADガイドラインを定めています。このガイドラインは2020年に改訂され、診断基準だけでなく治療法も明記されました。例えば、炎症に関連したADは、副腎皮質ステロイド外用薬とタクロリムスを用いて治療されます。これにより、患者を体系的に治療することが容易になり、治療効果が向上します。

アトピー性皮膚炎治療薬市場レポートハイライト

• 生物製剤セグメントが市場を独占し、2024年の世界売上高の38.07%を占めました。生物学的製剤分野の成長は、高い有効性による生物学的製剤の需要増加、製品承認の増加、アトピー性皮膚炎向け生物学的製剤の強力なパイプラインの利用可能性によって増強されています。
• 2024年の市場シェアは39.73%で、外用薬セグメントが市場を独占しています。外用治療薬の安全性と有効性に加え、処方率の高さと手ごろな価格が、その普及に大きく寄与しています。
• 病院薬局セグメントは、2024年に61.11%という大きな市場シェアを占めました。中等度から重度のアトピー性皮膚炎患者の多くは処方箋薬を必要とするが、病院薬局ではより容易に入手できることが多いです。
• 北米のアトピー性皮膚炎治療薬市場は、2024年に45.12%のシェアを占めました。これは、生物学的製剤や局所治療薬の採用率が高いことに起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 アトピー性皮膚炎治療薬市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• アトピー性皮膚炎治療薬市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • パイプライン分析

第4章 アトピー性皮膚炎治療薬市場：薬剤クラス別の推定・動向分析

• 世界のアトピー性皮膚炎治療薬市場：薬剤クラス別のダッシュボード
• 世界のアトピー性皮膚炎治療薬市場：薬剤クラス別の変動分析
• 薬剤クラス別の収益
• コルチコステロイド
• カルシニューリン阻害剤
• PDE4阻害剤
• 生物学的製剤
• その他

第5章 アトピー性皮膚炎治療薬市場：投与経路別の推定・動向分析

• 世界のアトピー性皮膚炎治療薬市場：投与経路別のダッシュボード
• 世界のアトピー性皮膚炎治療薬市場：投与経路別の変動分析
• 投与経路別の収益
• 局所
• 非経口
• 経口

第6章 アトピー性皮膚炎治療薬市場：流通チャネル別の推定・動向分析

• 世界のアトピー性皮膚炎治療薬市場：流通チャネル別のダッシュボード
• 世界のアトピー性皮膚炎治療薬市場：流通チャネル別の変動分析
• 流通チャネル別の収益
• 病院薬局
• 小売薬局
• その他の薬局

第7章 アトピー性皮膚炎治療薬市場：地域別の推定・動向分析

• 地域ダッシュボード
• 市場規模と予測および動向分析（2018年～2030年）
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • Key customers
  • Key company market share analysis, 2024
  • Pfizer Inc.
  • Sanofi
  • AbbVie Inc.
  • GALDERMA LABORATORIES, LP
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals Inc.
  • LEO Pharma Inc.
  • Otsuka Pharmaceutical Co., Ltd
  • Novartis AG
  • Incyte Corporation

List of Tables

• Table 1 List of abbreviation
• Table 2 North America atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
• Table 3 North America atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 4 North America atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 5 North America atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 6 U.S. atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 7 U.S. atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 8 U.S. atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 9 Canada atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 10 Canada atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 11 Canada atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 12 Mexico atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 13 Mexico atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 14 Mexico atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 15 Europe atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
• Table 16 Europe atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 17 Europe atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 18 Europe atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 19 Germany atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 20 Germany atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 21 Germany atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 22 UK atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 23 UK atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 24 UK atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 25 France atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 26 France atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 27 France atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 28 Italy atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 29 Italy atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 30 Italy atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 31 Spain atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 32 Spain atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 33 Spain atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 34 Denmark atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 35 Denmark atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 36 Denmark atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 37 Sweden atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 38 Sweden atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 39 Norway atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 40 Norway atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 41 Norway atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 42 Asia Pacific atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 45 Aisa Pacific atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 46 China atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 47 China atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 48 China atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 49 Japan atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 50 Japan atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 51 Japan atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 52 India atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 53 India atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 54 India atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 55 South Korea atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 56 South Korea atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 57 South Korea atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 58 Australia atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 59 Australia atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 60 Australia atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 61 Thailand atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 62 Thailand atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 63 Thailand atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 64 Latin America atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
• Table 65 Latin America atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 66 Latin America atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 67 Latin America atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 68 Brazil atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 69 Brazil atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 70 Brazil atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 71 Argentina atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 72 Argentina atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 73 Argentina atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 74 MEA atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
• Table 75 MEA atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 76 MEA atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 77 MEA atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 78 South Africa atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 79 South Africa atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 80 South Africa atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 81 Saudi Arabia atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 84 UAE atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 85 UAE atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 86 UAE atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 87 Kuwait atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 88 Kuwait atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 89 Kuwait atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Atopic dermatitis drugs market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Atopic dermatitis drugs market segment snapshot
• Fig. 10 Atopic dermatitis drugs market competitive snapshot
• Fig. 11 Atopic dermatitis drugs market driver impact
• Fig. 12 Atopic Dermatitis Drugs market restraint impact
• Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
• Fig. 14 Porter's five forces analysis
• Fig. 15 Value chain analysis
• Fig. 16 Atopic dermatitis drugs market: Drug class outlook and key takeaways
• Fig. 17 Atopic dermatitis drugs market: Drug class movement analysis
• Fig. 18 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Calcineurin Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 PDE4 Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Biologics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Atopic Dermatitis Drugs market: Route of administration outlook and key takeaways
• Fig. 24 Atopic Dermatitis Drugs market: Route of administration movement analysis
• Fig. 25 Topical market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Oral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Atopic Dermatitis Drugs market: Distribution channel outlook and key takeaways
• Fig. 29 Atopic Dermatitis Drugs market: Distribution channel movement analysis
• Fig. 30 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Other pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Global Atopic Dermatitis Drugs market: Regional movement analysis
• Fig. 34 Global Atopic Dermatitis Drugs market: Regional outlook and key takeaways
• Fig. 35 Global Atopic Dermatitis Drugs market share and leading players
• Fig. 36 North America, by country
• Fig. 37 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 U.S. key country dynamics
• Fig. 39 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Canada key country dynamics
• Fig. 41 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Mexico key country dynamics
• Fig. 43 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 UK key country dynamics
• Fig. 46 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Germany key country dynamics
• Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 France key country dynamics
• Fig. 50 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Italy key country dynamics
• Fig. 52 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Spain key country dynamics
• Fig. 54 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Denmark key country dynamics
• Fig. 56 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Sweden key country dynamics
• Fig. 58 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Norway key country dynamics
• Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 China key country dynamics
• Fig. 63 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Japan key country dynamics
• Fig. 65 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 India key country dynamics
• Fig. 67 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Thailand key country dynamics
• Fig. 69 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 South Korea key country dynamics
• Fig. 71 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Australia key country dynamics
• Fig. 73 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Brazil key country dynamics
• Fig. 76 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Argentina key country dynamics
• Fig. 78 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 South Africa key country dynamics
• Fig. 81 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Saudi Arabia key country dynamics
• Fig. 83 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 UAE key country dynamics
• Fig. 85 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Kuwait key country dynamics
• Fig. 87 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Market share Analysis of key market players, 2024

Atopic Dermatitis Drugs Market Growth & Trends:

The global atopic dermatitis drugs market size is expected to reach USD 29.88 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.02% from 2025 to 2030. The market for atopic dermatitis (AD) drugs is expected to witness growth opportunities owing to factors such as the increasing prevalence of atopic dermatitis across the globe, rising awareness, and high demand for treatment. Furthermore, the ongoing launch of innovative products to capture the market is a key strategy adopted by the players to gain market share and maintain their dominance.

A rising number of products in the pipeline, which are highly effective and show fewer adverse effects, is expected to drive the market. For instance, overall, 11 novel drugs indicated for atopic dermatitis are anticipated to be launched in the global market between 2020 and 2029. These include the following drug classes: Janus Kinase (JAK) inhibitors, phosphodiesterase-4 (PDE-4), and interleukin-4 & -13 (IL-4/13). These launches offer improvement in the quality of life and additional choices of treatments to patients with severe and moderate forms of AD.

Support from regulatory authorities, such as the provision of fast-track designation, is anticipated to impel R&D on AD. For instance, Lebrikizumab by Demira, Inc. received a fast-track designation. Moreover, in October 2020, Forte Biosciences, Inc.'s drug FB-401 was granted the fast-track designation by the FDA. Hence, the growing interest of companies in R&D is expected to propel the growth of the market.

An increase in funding for research and development of novel therapies for atopic dermatitis combined with proactive government initiatives will boost regional growth. Collaborations between public and private associations are expected to increase consumer awareness across the globe. For instance, in June 2022, Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.) announced the launch of Moizerto ointment (difamilast) for treating AD in Japan. This ointment is a non-steroidal topical phosphodiesterase type-4 inhibitor.

The Japanese Dermatological Association (JDA) provides AD guidelines for AD in Japan. These guidelines were revised in 2020, specifying diagnostic criteria as well as treatments. For instance, inflammation-related AD is treated using topical corticosteroids and tacrolimus. This facilitates the treatment of patients in a systematic manner, thus improving treatment efficacy.

Atopic Dermatitis Drugs Market Report Highlights:

• The biologics segment dominated the market and accounted for 38.07% of the global revenue in 2024. The growth of the biologics segment is augmented by rising demand for biologics due to high efficacy, rising product approvals, and availability of a robust pipeline of biologic drugs for atopic dermatitis.
• Topical segment dominated the market with a market share of 39.73% in 2024. The high prescription rates and affordability of medications, combined with the safety and efficacy of topical treatments, contribute significantly to their widespread use.
• The hospital pharmacies segment held a considerable market share of 61.11% in 2024. Many patients with moderate to severe atopic dermatitis require prescription medications, which are often more readily available through hospital pharmacies.
• The North America atopic dermatitis drugs market accounted for 45.12% share in 2024. This can be attributed to the high adoption rates of biologics and topical treatments.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Route of Administration
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and Route of Administration outlook
  • 2.2.2. Route of administration and distribution channel outlook
• 2.3. Competitive Insights

Chapter 3. Atopic Dermatitis Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidence of atopic dermatitis
    • 3.2.1.2. Rising awareness about disease
    • 3.2.1.3. Technological advancement
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Stringent regulations pertaining to drug approval
• 3.3. Atopic Dermatitis Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. Atopic Dermatitis Drugs Market: Drug Class Estimates & Trend Analysis

• 4.1. Global Atopic Dermatitis Drugs Market: Drug Class Dashboard
• 4.2. Global Atopic Dermatitis Drugs Market: Drug Class Movement Analysis
• 4.3. Global Atopic Dermatitis Drugs Market By Drug Class, Revenue
• 4.4. Corticosteroids
  • 4.4.1. Corticosteroids market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Calcineurin Inhibitors
  • 4.5.1. Calcineurin Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. PDE4 Inhibitors
  • 4.6.1. PDE4 inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Biologics
  • 4.7.1. Biologics market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Atopic Dermatitis Drugs Market: Route of Administration Estimates & Trend Analysis

• 5.1. Global Atopic Dermatitis Drugs Market: Route of Administration Dashboard
• 5.2. Global Atopic Dermatitis Drugs Market: Route of Administration Movement Analysis
• 5.3. Global Atopic Dermatitis Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
• 5.4. Topical
  • 5.4.1. Topical market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Parenteral
  • 5.5.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Oral
  • 5.6.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Atopic Dermatitis Drugs Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Global Atopic Dermatitis Drugs Market: Distribution Channel Dashboard
• 6.2. Global Atopic Dermatitis Drugs Market: Distribution Channel Movement Analysis
• 6.3. Global Atopic Dermatitis Drugs Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Other Pharmacies
  • 6.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Atopic Dermatitis Drugs Market: Regional Estimates & Trend Analysis By Product, Application, and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Pfizer Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Sanofi
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. AbbVie Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. GALDERMA LABORATORIES, L.P.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Eli Lilly and Company
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Regeneron Pharmaceuticals Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. LEO Pharma Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Otsuka Pharmaceutical Co., Ltd
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Novartis AG
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Incyte Corporation
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives